First Western Trust Bank Sells 801 Shares of Thermo Fisher Scientific Inc. $TMO

First Western Trust Bank lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,467 shares of the medical research company’s stock after selling 801 shares during the quarter. First Western Trust Bank’s holdings in Thermo Fisher Scientific were worth $3,839,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMO. ABN Amro Investment Solutions bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at approximately $60,939,000. Police & Firemen s Retirement System of New Jersey boosted its position in shares of Thermo Fisher Scientific by 3.2% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 57,367 shares of the medical research company’s stock valued at $23,260,000 after acquiring an additional 1,777 shares during the period. Bailard Inc. grew its stake in shares of Thermo Fisher Scientific by 142.4% in the second quarter. Bailard Inc. now owns 6,849 shares of the medical research company’s stock worth $2,777,000 after acquiring an additional 4,024 shares during the last quarter. Renasant Bank increased its position in Thermo Fisher Scientific by 59.6% during the second quarter. Renasant Bank now owns 2,453 shares of the medical research company’s stock worth $995,000 after acquiring an additional 916 shares during the period. Finally, Everett Harris & Co. CA raised its stake in Thermo Fisher Scientific by 5.1% during the 2nd quarter. Everett Harris & Co. CA now owns 15,455 shares of the medical research company’s stock valued at $6,266,000 after purchasing an additional 746 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $65,247,057.48. The trade was a 13.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the transaction, the executive vice president owned 21,152 shares of the company’s stock, valued at approximately $12,144,420.80. The trade was a 1.86% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 46,645 shares of company stock worth $25,825,699. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $588.53 on Thursday. The stock’s fifty day simple moving average is $524.35 and its 200 day simple moving average is $465.87. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The firm has a market cap of $221.12 billion, a price-to-earnings ratio of 34.00, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same period last year, the business earned $5.28 earnings per share. The business’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. TD Cowen boosted their price objective on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Barclays lifted their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Finally, Argus raised their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Nineteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.